S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
How does the Consumer Price Index affect the stock market?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
A 'soft landing' or a recession? How each one might affect America's households and businesses
Closing prices for crude oil, gold and other commodities
New CBOE “special perk” helps traders target income every weekend (Ad)
How major US stock indexes fared Friday, 12/8/2023
MarketBeat Week in Review – 12/4 - 12/8
New CBOE “special perk” helps traders target income every weekend (Ad)
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
How does the Consumer Price Index affect the stock market?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
A 'soft landing' or a recession? How each one might affect America's households and businesses
Closing prices for crude oil, gold and other commodities
New CBOE “special perk” helps traders target income every weekend (Ad)
How major US stock indexes fared Friday, 12/8/2023
MarketBeat Week in Review – 12/4 - 12/8
New CBOE “special perk” helps traders target income every weekend (Ad)
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
How does the Consumer Price Index affect the stock market?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
A 'soft landing' or a recession? How each one might affect America's households and businesses
Closing prices for crude oil, gold and other commodities
New CBOE “special perk” helps traders target income every weekend (Ad)
How major US stock indexes fared Friday, 12/8/2023
MarketBeat Week in Review – 12/4 - 12/8
New CBOE “special perk” helps traders target income every weekend (Ad)
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
How does the Consumer Price Index affect the stock market?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
A 'soft landing' or a recession? How each one might affect America's households and businesses
Closing prices for crude oil, gold and other commodities
New CBOE “special perk” helps traders target income every weekend (Ad)
How major US stock indexes fared Friday, 12/8/2023
MarketBeat Week in Review – 12/4 - 12/8
New CBOE “special perk” helps traders target income every weekend (Ad)
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company

Viking Therapeutics Stock Price, News & Analysis (NASDAQ:VKTX)

$18.48
+0.44 (+2.44%)
(As of 12/8/2023 ET)
Compare
Today's Range
$17.70
$19.58
50-Day Range
$9.24
$18.48
52-Week Range
$3.54
$25.72
Volume
4.67 million shs
Average Volume
2.52 million shs
Market Capitalization
$1.85 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.25

Viking Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
63.7% Upside
$30.25 Price Target
Short Interest
Bearish
16.96% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.88
Upright™ Environmental Score
News Sentiment
0.19mentions of Viking Therapeutics in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.92) to ($1.10) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

441st out of 942 stocks

Pharmaceutical Preparations Industry

193rd out of 446 stocks


VKTX stock logo

About Viking Therapeutics Stock (NASDAQ:VKTX)

Founded in 2012, Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California. The company is focused on developing novel therapies for metabolic and endocrine disorders, including non-alcoholic steatohepatitis (NASH), hip fracture recovery, and type 2 diabetes. Viking's mission is to bring life-changing treatments to patients with unmet medical needs.

Viking's lead product candidate, VK2809, is a small molecule thyroid beta receptor agonist currently being evaluated in a Phase 2b clinical trial for treating NASH. The company's other product candidates include VK0214, a liver-directed thyroid receptor beta agonist for treating X-linked adrenoleukodystrophy (X-ALD), and VK0612, a novel PPAR-delta agonist for the treatment of type 2 diabetes.

Viking's management team is led by Chief Executive Officer Brian Lian, who joined the company in 2016. Lian has over 25 years of experience in the biotech and pharmaceutical industries, including senior leadership roles at InterMune, Abgenix, and Bristol-Myers Squibb. 

Viking is working hard to grow its revenue. However, the company has yet to turn a profit, reporting a net loss of $68 million in 2022 which increased from 2021's reported $-55 million loss. Viking has also been actively raising capital, recently completing a public offering of common stock.

Viking's current market capitalization is around $1.9 billion, with a price-to-book ratio that aligns with industry peers. Still, some investors see the potential for significant upside if Viking's clinical trials are successful.

Viking's stock price has been volatile over the recent past. The stock has seen a slight uptick recently due to positive news about its drugs in clinical trials. The company's trading volume has been increasing steadily, indicating investor interest.

Viking operates in the highly competitive biotech industry, where companies must navigate complex regulatory environments and rapidly evolving technologies. The NASH market, in particular, is highly competitive, with several large pharmaceutical companies developing therapies for the disease. However, Viking's focus on novel mechanisms of action and expertise in metabolic and endocrine disorders give the company a competitive advantage. Additionally, Viking's partnerships with established biotech companies, such as Ligand Pharmaceuticals and Bayer, provide the company with valuable resources and expertise.

Viking has several potential growth opportunities in the pipeline, including the ongoing Phase 2b clinical trial of VK2809 for treating NASH. If the trial succeeds, Viking could partner with a larger pharmaceutical company to bring the therapy to market. The company's other product candidates, including VK0214 and VK0612, also have the potential to address significant unmet medical needs. Viking has also explored expansion opportunities into new therapeutic areas, such as oncology.

Viking Therapeutics faces a risk from the possibility of regulatory changes affecting the approval of its products. The pharmaceutical industry is heavily regulated, and any changes in regulations or policies could impact Viking's ability to bring its products to market or receive approval for clinical trials. In addition, the company's competitors may also receive approval for similar products, reducing the market share available to Viking.

Risk management is an integral part of any business strategy, and Viking Therapeutics is taking steps to mitigate the risks it faces. The company has a diverse pipeline of products, which helps reduce the impact of any one product failing. Viking is also conducting extensive clinical trials to ensure the safety and efficacy of its products, which could increase the likelihood of approval and reduce the risk of adverse events.

VKTX Stock Price History

VKTX Stock News Headlines

Viking Therapeutics Inc VKTX
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Viking Therapeutics (NASDAQ:VKTX) Trading Down 3.2%
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
What's Going On With Viking Therapeutics Shares Tuesday?
VKTX Oct 2023 10.500 call
Q3 2023 Viking Therapeutics Inc Earnings Call
See More Headlines
Receive VKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viking Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/25/2023
Today
12/09/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/14/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VKTX
Fax
N/A
Employees
23
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$30.25
High Stock Price Target
$37.00
Low Stock Price Target
$19.00
Potential Upside/Downside
+63.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

Net Income
$-68,870,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.89 per share

Miscellaneous

Free Float
95,628,000
Market Cap
$1.85 billion
Optionable
Optionable
Beta
0.61
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for December 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Brian Lian Ph.D. (Age 57)
    President, CEO & Director
    Comp: $965.12k
  • Mr. Gregory S. Zante (Age 52)
    Chief Financial Officer
    Comp: $603.5k
  • Ms. Marianne Mancini (Age 58)
    Chief Operating Officer
    Comp: $633.3k
  • Mr. Michael Morneau (Age 58)
    Vice President of Finance & Administration
    Comp: $375.33k
  • Dr. Geoffrey E. Barker Ph.D.
    Senior Vice President of Pharmaceutical Development














VKTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Viking Therapeutics stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viking Therapeutics in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VKTX shares.
View VKTX analyst ratings
or view top-rated stocks.

What is Viking Therapeutics' stock price target for 2024?

9 Wall Street research analysts have issued 12 month price targets for Viking Therapeutics' stock. Their VKTX share price targets range from $19.00 to $37.00. On average, they anticipate the company's stock price to reach $30.25 in the next twelve months. This suggests a possible upside of 63.7% from the stock's current price.
View analysts price targets for VKTX
or view top-rated stocks among Wall Street analysts.

How have VKTX shares performed in 2023?

Viking Therapeutics' stock was trading at $9.40 at the beginning of the year. Since then, VKTX shares have increased by 96.6% and is now trading at $18.48.
View the best growth stocks for 2023 here
.

When is Viking Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 14th 2024.
View our VKTX earnings forecast
.

How were Viking Therapeutics' earnings last quarter?

Viking Therapeutics, Inc. (NASDAQ:VKTX) posted its quarterly earnings data on Wednesday, October, 25th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by $0.01.

What ETFs hold Viking Therapeutics' stock?
What other stocks do shareholders of Viking Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Viking Therapeutics investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), SCYNEXIS (SCYX), Amarin (AMRN), Advanced Micro Devices (AMD), Verastem (VSTM), Energy Transfer (ET) and Inovio Pharmaceuticals (INO).

When did Viking Therapeutics IPO?

(VKTX) raised $20 million in an IPO on Wednesday, April 29th 2015. The company issued 2,500,000 shares at a price of $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. acted as the underwriter for the IPO and Feltl and Company was co-manager.

Who are Viking Therapeutics' major shareholders?

Viking Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), American Century Companies Inc. (2.20%), Deerfield Management Company L.P. Series C (1.28%), Northern Trust Corp (0.93%), Invesco Ltd. (0.86%) and Charles Schwab Investment Management Inc. (0.77%). Insiders that own company stock include Brian Lian, Charles A Rowland Jr, Greg Zante, Lawson Macartney, Marianna Mancini and Matthew W Foehr.
View institutional ownership trends
.

How do I buy shares of Viking Therapeutics?

Shares of VKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:VKTX) was last updated on 12/9/2023 by MarketBeat.com Staff

My Account -